A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

India’s health regulator has approved Eli Lilly’s pre-filled pen version of Mounjaro, expanding its availability across six ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Eli Lilly ( LLY 0.82%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...